TTYH3 and neoplasm: Consequently, our data revealed that TTYH3 might function as a favorable tumor activator gene for bladder cancer and that the molecular basis underlying the TTYH3 and FGER1 mediated the MAPK signaling, which can be utilized in MAPK-based bladder cancer therapeutics approach and might hold potential clinical targets.